表紙:CAEL-101:新たな洞察と2030年までの市場予測
市場調査レポート
商品コード
974763

CAEL-101:新たな洞察と2030年までの市場予測

CAEL-101- Emerging Insight and Market Forecast - 2030

出版日: 受注後作成 | 発行: DelveInsight Business Research LLP | ページ情報: 英文 60 Pages | 納期: 2~10営業日

価格
価格表記: USDを日本円(税抜)に換算
本日の銀行送金レート: 1USD=134.29円
CAEL-101:新たな洞察と2030年までの市場予測
出版日: 受注後作成
発行: DelveInsight Business Research LLP
ページ情報: 英文 60 Pages
納期: 2~10営業日
  • 全表示
  • 概要
  • 図表
  • 目次
概要

当レポートは、主要7ヶ国市場(米国、欧州5ヶ国(ドイツ、フランス、イタリア、スペイン、英国)、および日本)におけるCAEL-101市場について調査しており、市場規模や2030年までの販売予測、製品概要、規制のマイルストーンやその他の開発活動、米国、欧州、日本全体の医薬品の研究開発活動、CAEL-101周辺の有効期限のタイムラインによる特許情報、臨床試験情報などを掲載しています。

目次

第1章 薬剤の概要

  • 製品の詳細
  • 作用機序
  • 投薬と管理
  • 研究開発活動
    • 臨床開発
    • 安全性と有効性
  • その他の開発活動

第2章 市場評価

  • 主要7ヶ国市場分析
  • 米国市場
  • ドイツ市場
  • フランス市場
  • イタリア市場
  • スペイン市場
  • 英国市場
  • 日本市場

第3章 SWOT分析

第4章 アナリストの見解

第5章 市場の競合

第6章 その他の新しい治療法

第7章 付録

第8章 購入オプションのレポート

図表

List of Tables

  • Table 1 CAEL-101, Description
  • Table 2 CAEL-101, Clinical Trial Description
  • Table 3 CAEL-101, 7MM Market Size from 2020 to 2030 (in Million USD)
  • Table 4 Market Competitors
  • Table 5 Other Emerging Therapies

List of Figures

  • Figure 1 The Development Timeline of CAEL-101
  • Figure 2 Patent Details, CAEL-101
  • Figure 3 CAEL-101, 7MM Market Size from 2020 to 2030 (in Million USD)
  • Figure 4 CAEL-101, US Market Size from 2020 to 2030 (in Millions USD)
  • Figure 5 CAEL-101, EU5 Market Size from 2020 to 2030 (in Millions USD)
  • Figure 6 CAEL-101, Japan Market Size from 2020 to 2030 (in Millions USD)
目次
Product Code: DIDM0144

"CAEL-101- Emerging Insight and Market Forecast - 2030" the report provides comprehensive insights about an investigational product for AL Amyloidosis in 7 Major Markets. A detailed picture of the CAEL-101 in Seven Major Markets, i.e., United States, EU5 (Germany, France, Italy, Spain, and the United Kingdom), and Japan, for the study period 2020-2030 is provided in this report along with a detailed description of the product. The product details cover mechanism of action, dosage and administration, route of synthesis, and Research and development activity including regulatory milestones, and other development activities. Further, it also consists of future market assessments inclusive of the market forecast, SWOT analysis, market competitors, and other emerging therapies.

Overview:

CAEL-101 is a fibril-reactive monoclonal antibody (mAb) that is currently in Phase 3 clinical development for the treatment of patients with amyloid light chain ("AL") amyloidosis. The Cardiac Amyloid Reaching for Extended Survival (CARES) clinical program includes two parallel Phase 3 studies - one in patients with Mayo stage IIIa disease and one in patients with Mayo stage IIIb disease - and will collectively enroll approximately 370 patients globally. Enrollment is underway in both studies. The primary objective of the clinical program is to assess overall survival.

Scope of the report:

The report provides insights into:

  • A comprehensive product overview including the product description, mechanism of action, dosage and administration, Research and Development activity.
  • Elaborated details on regulatory milestones and other development activities have been provided in this report.
  • The report also highlights the drug research and development activity details across the United States, Europe and Japan.
  • The report also covers the patents information with expiry timeline around CAEL-101.
  • The report contains forecasted sales for CAEL-101 till 2030.
  • Comprehensive coverage of the late-stage emerging therapies (Phase II) for AL Amyloidosis.
  • The report also features the SWOT analysis with analyst insights and key findings of CAEL-101.

Methodology:

The report is built using data and information sourced primarily from internal databases, primary and secondary research and in-house analysis by DelveInsight's team of industry experts. Information and data from the secondary sources have been obtained from various printable and nonprintable sources like search engines, news websites, global regulatory authorities websites, trade journals, white papers, magazines, books, trade associations, industry associations, industry portals and access to available databases.

CAEL-101 Analytical Perspective by DelveInsight

  • In-depth CAEL-101 Market Assessment

This report provides a detailed market assessment of CAEL-101 in Seven Major Markets, i.e., United States, EU5 (Germany, France, Italy, Spain, and the United Kingdom), and Japan. This segment of the report provides forecasted sales data from 2020 to 2030.

  • CAEL-101 Clinical Assessment

The report provides the clinical trials information of CAEL-101 covering trial interventions, trial conditions, trial status, start and completion dates.

Report highlights:

  • In the coming years, the market scenario for AL Amyloidosis is set to change due to the extensive research and incremental healthcare spending across the world; which would expand the size of the market to enable the drug manufacturers to penetrate more into the market.
  • The companies and academics are working to assess challenges and seek opportunities that could influence CAEL-101 dominance. The therapies under development are focused on novel approaches to treat/improve the disease condition.
  • Other emerging products for AL Amyloidosis are giving market competition to CAEL-101 and launch of late-stage emerging therapies in the near future will significantly impact the market.
  • A detailed description of regulatory milestones, development activities, and some key findings provide the current development scenario of CAEL-101.
  • Our in-depth analysis of the forecasted sales data of CAEL-101 from 2020 to 2030 will support the clients in the decision-making process regarding their therapeutic portfolio by identifying the overall scenario of the CAEL-101.

Key Questions:

  • Which company is developing CAEL-101 along with the phase of the clinical study?
  • What is the technology utilized in the development of CAEL-101?
  • What is the product type, route of administration and mechanism of action of CAEL-101?
  • What is the clinical trial status of the study and study completion date?
  • What are the key collaborations, mergers and acquisitions, licensing and other activities related to the CAEL-101 development?
  • What are the key designations that have been granted to CAEL-101?
  • What is the forecasted market scenario of CAEL-101?
  • What is the history of CAEL-101 and what is its future?
  • What is the forecasted sales of CAEL-101 in the seven major countries, including the United States, Europe (Germany, France, Italy, Spain, and the United Kingdom), and Japan?
  • What are the other emerging products available and how these are giving competition to CAEL-101?
  • Which are the late-stage emerging therapies under development for the treatment of the PPD?

Table of Contents

1. Drug Overview

  • 1.1. Product Detail
  • 1.2. Mechanism of Action
  • 1.3. Dosage and Administration
  • 1.4. Research and development activity
    • 1.4.1. Clinical Development
    • 1.4.2. Safety and Efficacy
  • 1.5. Other Development Activities

2. Market Assesment

  • 2.1. 7MM Market Analysis
  • 2.2. The United States Market
  • 2.3. Germany Market
  • 2.4. France Market
  • 2.5. Italy Market
  • 2.6. Spain Market
  • 2.7. United Kingdom Market
  • 2.8. Japan Market

3. SWOT Analysis

4. Analyst Views

5. Market Competitors

6. Other Emerging Therapies

7. Appendix

8. Report Purchase Options